Luong et al. have established that the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA), already FDA-approved for the treatment of several neoplastic diseases [4, 5], has antitumor activities against thyroid cancer [6]. The gene discussed is HDAC9; the disease is neoplasm.